{"data":{"id":572,"lang":"en","title":"Moderna Pays $2.25 Billion to Settle mRNA Vaccine Patent Fight With Arbutus and Genevant","summary":"Moderna settles $2.25B patent dispute over lipid nanoparticle technology used in its mRNA COVID vaccines.","category":"science","category_label":"Science","published_at":"2026-03-04T22:02:05Z","updated_at":"2026-03-04T22:02:05Z","url":"https://techtools.cz/tools/news/article/572-moderna-pays-2-25-billion-to-settle-mrna-vaccine-patent-fight-with-arbutus-and","api_url":"https://techtools.cz/news-api/v1/articles/572?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/572.md?lang=en","image_url":"https://imgproxy.divecdn.com/ExcQwxMCh7TndNANYr1lnlXC93Bw5yq2__tdeuk746k/g:nowe:0:646/c:5030:2842/rs:fill:1200:1200:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjg4NjcwMjc0LmpwZw==.webp","word_count":146,"reading_time_minutes":1,"sources":[{"url":"https://www.biopharmadive.com/news/moderna-roivant-arbutus-genevant-patent-settlement-mrna-vaccines/813792/","domain":"biopharmadive.com"},{"url":"https://www.statnews.com/2026/03/03/moderna-settles-covid-vaccine-suit-roivant/","domain":"statnews.com"}],"translation":{"lang":"cs","id":578,"title":"Moderna zaplatí 2,25 miliardy dolarů za urovnání patentového sporu o mRNA vakcíny s Arbutus a Genevant","url":"https://techtools.cz/tools/news/clanek/578-moderna-zaplati-2-25-miliardy-dolaru-za-urovnani-patentoveho-sporu-o-mrna","api_url":"https://techtools.cz/news-api/v1/articles/578?lang=cs"},"content":"Moderna has agreed to pay up to $2.25 billion to Arbutus Biopharma and Roivant subsidiary Genevant Sciences, ending a years-long legal battle over the lipid nanoparticle (LNP) technology critical to its mRNA COVID-19 vaccines. The settlement includes $950 million upfront in July 2026, with an additional $1.3 billion contingent on the outcome of a separate legal appeal.\n\nThe dispute centered on the fatty shells that deliver mRNA into human cells — a technology pioneered by Arbutus that Moderna used without a license. Under the deal, Moderna receives a global non-exclusive license for LNP delivery in infectious-disease mRNA vaccines and will owe no future royalties. Moderna shares jumped over 15% on the news, driving the stock up more than 95% year-to-date in 2026.\n\nArbutus and Genevant still have a separate ongoing patent lawsuit against Pfizer and BioNTech over the same LNP technology used in their competing COVID vaccine."}}